user
menu
letter
Sign InRegister
langEnglisharrow
Save Product

Ready-to-use hiPSC-Derived Dorsal Forebrain Organoids (Mature)

COA MS
DS

Customer Reviews
Cat. No. / Size
Price
Availability
Qty
CIPO-BWL02-5organoids (1organoid X 5)
Inquiry
Inquire about delivery time
CIPO-BWL02-20organoids (1organoid X 20)
Inquiry
Inquire about delivery time
CIPO-BWL02-100organoids (1organoid X 100)
Inquiry
Inquire about delivery time
Sub-Total$ 0
Customize Product
Quote Inquiry

Product Details

  • Product Details

    Human iPSC-Derived Dorsal Forebrain Organoids (Cat. No. CIPO-BWL02) are three-dimensional in vitro models that recapitulate key developmental and cellular features of the human dorsal forebrain. These organoids are generated from the human iPSC line ATCC-HYR0103 under ultra-low attachment (ULA) culture conditions using a self-assembly differentiation workflow. Human iPSC-Derived Dorsal Forebrain Organoids exhibit characteristic mature dorsal forebrain and cortical features, including MAP2-positive neurons, GFAP-positive astrocytes, OLIG2-positive oligodendroglial lineage cells, and spontaneous electrical activity. The organoids are shipped at ambient temperature in a ready-to-use format and can be maintained using the Human iPSC-Derived Dorsal Forebrain Organoid Maintenance Kit (Cat. No. RIPO-BWM01). This model is suitable for a range of applications, including studies of human brain development, neurological disease modeling, neurotoxicity assessment, neuronal excitability and network activity studies, and other neuroscience research.

  • Product Specification

    Ready-to-use hiPSC-Derived Dorsal Forebrain Organoids are delivered in a specialized shipping medium and require a short recovery period before downstream assays or experiments.

  • Storage

    Upon receipt, transfer the organoids to fresh maintenance medium as soon as possible and follow the appropriate incubation conditions and medium change schedule.

  • Shipping

    This product is supplied and shipped with blue ice, please inquire the shipping cost.

  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • Product Diagram

    Organoids PRODUCT DIAGRAM

    Workflow for dorsal forebrain organoid differentiation.

Validation

  • Marker Expression

    Organoids MARKER EXPRESSION

    Marker Expression in hiPSC-Derived Dorsal Forebrain Organoids
    At Day 27, the organoids expressed PAX6, TUJ1, and FOXG1 with minimal NKX2.1 expression, supporting a dorsal forebrain identity. By Day 57–87, the organoids showed progressive neuronal maturation and cellular diversification, with CTIP2- and MAP2-positive neurons, vGLUT1-positive excitatory neurons, GFAP-positive astrocytes, and OLIG2-positive cells.

    Protocol

  • Organoid Activity

    Organoids ORGANOID ACTIVITY

    Intra-batch morphological consistency
    Organoids within the same batch showed consistent growth and morphology over time, with diameter CVs (QC) ranging from approximately 4% to 15%, demonstrating good intra-batch consistency.

    Protocol
    Organoids ORGANOID ACTIVITY

    Inter-batch morphological consistency
    Organoids from three independent batches showed similar growth patterns and morphological (QC) changes, with consistent sizes across batches, demonstrating good inter-batch consistency.

    Protocol

  • Organoid Application

    Organoids ORGANOID APPLICATION

    Spontaneous calcium activity in dorsal forebrain organoids
    Dorsal forebrain organoids exhibited spontaneous, rhythmic calcium transients over a 180-s recording period using the FLIPR Calcium 6 assay, with clear periodic ΔF/F₀ oscillations (in video).

    Protocol
    Organoids ORGANOID APPLICATION

    Electrophysiological profiling of hiPSC-derived dorsal forebrain organoids by MEA
    All 5/5 dorsal forebrain organoids exhibited robust spontaneous electrophysiological activity (QC), with clear waveforms recorded over a 6-min MEA measurement period (in video).

    Protocol
    Organoids ORGANOID APPLICATION

    Compound-Induced Neuronal Hyperexcitability
    Glutamate and Yoda1 treatment increased neuronal activity compared with baseline, with higher spike numbers, more active electrodes, and denser spiking patterns. Yoda2 produced a stronger response, particularly in firing rate, demonstrating that MEA-based brain organoids can capture compound-induced neuronal hyperexcitability and support neuroactive compound screening.

    Protocol

Customer Reviews
Writing Reviews

Recent Advances

 
Contact Us
Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews